Literature DB >> 34848834

Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant.

Luisa Giaccone1,2, Lucia Brunello3,4, Jaime Suarez Londono5, Matilde Scaldaferri6, Marco Cerrano3,4, Valter Redoglia3,4, Paola Omedè3, Giuseppe Lia3,4, Massimo Massaia4, Dario Ferrero3,4, Federica Cavallo3,4, Sara Bringhen3, Sarah Leone7, Francesco Cattel6, Tiziana Francisci8, Valter Tassi8, Andrea Evangelista9, Mario Boccadoro3,4, Benedetto Bruno3,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34848834     DOI： 10.1038/s41409-021-01541-1

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  2 in total

1.  A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer.

Authors:  Cornelius F Waller; Vladimir F Semiglazov; Sergei Tjulandin; Dmitry Bentsion; Stephen Chan; Rodeina Challand
Journal:  Onkologie       Date:  2010-09-06

2.  Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens.

Authors:  Simona Bassi; Elisa M Stroppa; Carlo F Moroni; Maria C Arbasi; Elena Trabacchi; Anna Di Franco; Antonio Lazzaro; Patrizia Bernuzzi; Mauro Moretto; Annalisa Arcari; Costanza Bosi; Alessandra Riva; Luigi Cavanna; Daniele Vallisa
Journal:  Blood Transfus       Date:  2015-02-02       Impact factor: 3.443
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.